Pharmaceutical Market Europe • January 2023 • 34-36
APPOINTMENTS
AstraZeneca
David Brocklehurst
AstraZeneca has appointed David Brocklehurst as UK head of oncology. Brocklehurst will be responsible for overseeing the company’s oncology team and cancer care standards in the UK. He will also be responsible for all aspects of its portfolio and pipeline in oncology and will lead the delivery of its leadership initiatives and will manage partnerships to help the NHS optimise cancer services. Brocklehurst has been with AstraZeneca for 13 years and in his most recent role as vice president, oncology business unit head for the Nordics, was in charge of bringing all of the company’s oncology medicines to cancer patients in Denmark, Norway, Sweden, Finland and Iceland. He previously served at McCann Health as a senior strategy associate and at Adelphi Group as a senior research associate.
TestCard
Elmer Monster
TestCard has appointed Elmer Monster as chief executive officer. Monster has over 20 years of experience across the healthcare industry, having held various senior leadership roles in commercial, finance and strategy at Roche across both the pharmaceuticals and diagnostics divisions. He recently served as chief financial officer at Swiss medtech company Coretag, and was appointed to TestCard’s board.
Aerami Therapeutics
Lisa Yañez
Aerami Therapeutics has appointed Lisa Yañez as chief executive officer. Yañez joined Aerami Therapeutics as chief operating officer earlier this year and has over 25 years’ experience at leading pharmaceutical and biotechnology companies, serving at Merck, Genentech, GSK, and most recently, United Therapeutics and Acceleron Pharma. At Acceleron, she spearheaded clinical development initiatives.
Emmes
Ching Tian
Emmes has appointed Ching Tian as its chief innovation officer. Before Emmes, Tian was senior vice president of strategy and solutions at Medable. She served at Novartis, where she was general manager, data and digital, in global drug development and at MedImmune and AstraZeneca, where she held roles of increasing responsibility in areas including global pharmacovigilance systems and statistical programming.
ONK Therapeutics
Bruce McCreedy
ONK Therapeutics has appointed Bruce McCreedy as chief scientific officer. An immunologist and gene therapy expert, McCreedy has over three decades of experience in drug development. He previously served at Myeloid Therapeutics as chief scientific officer, as SVP, Cell Therapy and Immuno-Oncology Research at Precision Biosciences and was also executive vice president and chief development officer for Neximmune.
Rentschler Biopharma
Frank Mathias
Rentschler Biopharma has appointed Frank Mathias to its supervisory board. Mathias’ role will begin in March 2023. Mathias joined Rentschler Biopharma’s Supervisory Board in 2013 and was appointed chief executive officer (CEO) and chairman of the executive board in April 2016. He was CEO at Medigene and between 2002 and 2008, was corporate vice president and general manager at Amgen.
Onconova Therapeutics
Peter Atadja
Onconova Therapeutics has appointed Peter Atadja as a member of its board of directors. Atadja serves as chief scientific officer of CommBio Therapeutics and previously co-founded and served as the chief scientific officer at K36 Therapeutic. Between 1997 and 2021, he held several roles at Novartis Pharmaceuticals, most recently serving as its executive director and head, drug discovery and translational research.
Onconova Therapeutics
Trafford Clarke
Onconova Therapeutics has appointed Trafford Clarke as an independent member of its board of directors. Clarke worked at Eli Lilly for 31 years, and recently served as a managing director and UK research and development site head. He served as Eli Lilly’s European Federation of Pharmaceutical Industries and Associations R&D representative and was a member of the Research Directors Group.
BiondVax Pharmaceuticals
Matthias Dobbelstein
BiondVax Pharmaceuticals has appointed Matthias Dobbelstein to its scientific advisory board. Dobbelstein has served as director of the Institute of Molecular Oncology at the University Medical Center Göttingen, Germany and is an associate member of the Max Planck Institute for Multidisciplinary Sciences. He has also done research as a virologist and cancer biologist at Princeton University.
AstraZeneca
Tina Batchelor
AstraZeneca has appointed Tina Batchelor as its UK director of communications. Batchelor’s appointment follows the departure of Elisa Agate who covered the role on an interim basis. She joins the company from the NHS, where she spearheaded communications and engagement at Hertfordshire Community NHS Trust. As well as providing 50 different community healthcare services, Batchelor’s NHS Trust was one of the main providers of the COVID-19 vaccination in Hertfordshire. Throughout the pandemic, she led the Trust’s communications efforts, working in partnership with various stakeholders to drive uptake of the COVID-19 vaccination, including engagement with schools and councils across the East of England to deliver the vaccination. Prior to the NHS, she spent 12 years at Roche, most recently as its head of corporate affairs.
Incyte
Peter Williams
Incyte has appointed Peter Williams as general manager for Incyte Biosciences, UK and Ireland. With over 20 years of pharmaceutical industry experience, Williams brings a strong background covering commercial functions and senior management roles. Prior to Incyte, he served as senior director for sales and marketing at Gilead Sciences UK and as business unit director at AbbVie UK.
STADA
Stéphane Jacqmin
STADA has appointed Stéphane Jacqmin as head of emerging markets. Jacqmin has international experience in pharmaceutical and consumer goods settings, having worked at Unilever and Reckitt Benckiser. In 2012, he joined Sanofi Consumer Healthcare, initially as business unit director for the Czech Republic and Slovakia, before recently becoming region head, Latin America, at Sanofi Consumer Healthcare.
Kry
Lukas Didon
Kry has appointed Lukas Didon as commercial and partnerships vice president. Didon brings more than 20 years’ professional and international experience in driving strategic growth and business transformation in healthcare. He has worked as a management consultant for companies such as Deloitte where he served from 2017 to 2021 and at Synpulse Management Consulting for over three years.
GeoVax Labs
Valerie Montgomery Rice
GeoVax Labs has appointed Valerie Montgomery Rice as special advisor to the chairman/chief executive officer and board of directors. She is the first woman to be president and CEO of the Morehouse School of Medicine. She has experience of healthcare leadership, patient care, biomedical research and public health policy, and has been appointed to the President’s Committee on the National Medal of Science.
ADC Therapeutics
Jose Carmona
ADC Therapeutics has appointed Jose Carmona as chief financial officer. Carmona has over 20 years of leadership, commercial and partnership experience in pharmaceuticals, having recently served as chief financial officer of Rubius Therapeutics. Before Rubius, he was chief financial officer at Radius Health and Innocoll. He served for 12 years at Novartis, in positions covering Europe, Middle East and Africa.
GeoVax Labs
Jayne Morgan
GeoVax Labs has appointed Jayne Morgan to its board of directors. Morgan is an accomplished healthcare management executive and research leader with extensive experience in complex hospital and corporation navigation, as well as leadership in COVID-19 management, crisis mitigation, health equity and clinical trials. She currently serves as executive clinical director of the COVID Task Force at Piedmont Healthcare.
Sphere Fluidics
Richard Hammond
Sphere Fluidics has appointed Richard Hammond as chief technical officer. Hammond has over 20 years’ experience in managing the development of cutting-edge commercial products for healthcare and life sciences. He has held numerous senior positions at Alere, Cambridge Consultants and DNA Electronics. Hammond holds MA and MEng degrees in engineering from King’s College, University of Cambridge.
Clasado Biosciences
Heather Solomita
Clasado Biosciences has appointed Heather Solomita as North American sales manager. Solomita brings a wealth of experience in prebiotic applications, having most recently served in business development at Prenexus Health. She was previously an account manager for Catalyst Nutraceuticals and a business development account manager for Neptune Wellness Solutions, and also worked at AlzChem.
Lumanity
Sam Chapman
Lumanity has appointed Sam Chapman as its client services director. Chapman has over eight years’ experience in the industry, having recently served at Inpharmation as head of business development. He also served at Inpharmation as a manager, a senior consultant and as a business development consultant. Prior to that, he served as a project associate at PSI CRO AG.
IGNIFI
Joe McCarthy
IGNIFI has appointed Joe McCarthy as its strategic healthcare director. McCarthy has a strong background in pharmaceuticals, having worked with clients in the industry for over 30 years. He has extensive experience of working with major brands. Prior to joining IGNIFI, he served as marketing manager at Pharmacosmos where he was responsible for strategic planning.
M+F Health
Marie Lane
M+F Health has appointed Marie Lane as director. Lane has over ten years’ experience working with patient advocacy groups and pharma, having served within communications teams at Pfizer and Sanof. In 2013, Lane served as an account manager at Health Unlimited, ahead of being made senior account director. She also served at Porter Novelli as an account manager.
M+F Health
Andie Gbedemah
M+F Health has appointed Andie Gbedemah as senior account director. Gbedemah joined the agency just under a year ago as an account director on the Public Affairs team and worked on Janssen Health Inequalities, the Bowel Cancer APPG, Novartis and BASHH (British Association for Sexual Health and HIV). She previously served at Dimensions UK as head of public affairs.
90Ten
Olivia Kuhn
90Ten has appointed Olivia Kuhn as account supervisor. Kuhn brings a wealth of experience to the role, having served at BCW Global as a senior account executive, health media. Prior to that, she served at Edelman for over two years, working as a media executive. Between 2017 and 2018, she completed communications internships at crisp and LM Restaurant Group.
M+F Health
Georgia Bron
M+F Health has appointed Georgia Bron as account manager. Bron has served at the agency for the past two years, beginning as a public relations intern before being promoted to the role of senior account executive. Prior to joining the agency, she worked at Fundscape as a digital marketing executive and prior to that, she worked on the good-cause campaign team at Magpie.
M+F Health
Kirsty Baldry
M+F Health has appointed Kirsty Baldry as an account manager. Baldry has served at M+F Health for over two years, beginning her healthcare communications journey as an intern in 2020, before moving on up into positions as an account executive and then as senior account executive in October 2021. She previously served at Pentland Brands as part of her internship.
M+F Health
Vlada Shevelkova
M+F Health has appointed Vlada Shevelkova as an account manager. Shevelkova previously served at the Department of Health and Social Care, overseeing the health policy fast-track scheme, and also served as policy manager, EU Exit. She served as a trend reporter for Public Health Pathways and also served at Africa Health Organisation as a health policy researcher and trustee.
90Ten
Emily Tridimas
90Ten has appointed Emily Tridimas as an associate medical writer. Tridimas is a qualified doctor, having studied at the University of Birmingham and King's College London. She previously worked with patients at Guys’ and St Thomas’ NHS Foundation Trust for three years, at Epsom and St Helier University Hospitals NHS Trust and also at Frimley Park Hospital NHS Foundation Trust.
Onyx Health
Modupe Ayeni
Onyx Health has appointed Modupe Ayeni as a medical writer. Ayeni brings specialist knowledge and expertise to her new role, having earned a Batchelor of Science and a PhD in Cardiovascular Science from the University of Leicester. She previously worked as a PhD researcher at the University of Leicester and later taught science in Middlesbrough, as part of the Outwood Academy Trust.
OPEN Health
David King
OPEN Health has appointed David King as non-executive chairman. King served for 13 years as chairman and chief executive officer of LabCorp, where he oversaw the company’s transformation from a clinical laboratory into a global leader in life sciences. He played a key role in the expansion of offerings for pharmaceutical and biotech companies, including leading the acquisition of Covance.
OPEN Health
Paul Carter
OPEN Health has appointed Paul Carter as an independent board member. Carter was previously executive vice president and chief commercial officer at Gilead, where he was responsible for international growth and commercial success. As head of commercial operations for international markets at Gilead, he worked to build the Gilead commercial infrastructure in 38 countries over eight years.